These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37940790)

  • 1. Repurposing of Strychnine as the Potential Inhibitors of Aldo-keto Reductase Family 1 Members B1 and B10: Computational Modeling and Pharmacokinetic Analysis.
    Sarfraz M; Aziz M; Afzal S; Channar PA; Alsfouk BA; Kandhro GA; Hassan S; Sultan A; Hamad A; Arafat M; Qaiser MN; Ahmed A; Siddique F; Ejaz SA
    Protein J; 2024 Apr; 43(2):207-224. PubMed ID: 37940790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of Phenylcarbamoylazinane-1,2,4-Triazole Amides Derivatives as the Potential Inhibitors of Aldo-Keto Reductases (AKR1B1 & AKRB10): Potential Lead Molecules for Treatment of Colon Cancer.
    Saeed A; Ejaz SA; Sarfraz M; Tamam N; Siddique F; Riaz N; Qais FA; Chtita S; Iqbal J
    Molecules; 2022 Jun; 27(13):. PubMed ID: 35807227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-silico Investigations of quinine and quinidine as potential Inhibitors of AKR1B1 and AKR1B10: Functional and structural characterization.
    Ejaz SA; Saeed A; Birmani PR; Katubi KM; Elqahtani ZM; Al-Buriahi MS; Ujan R; Siddique F; Ahmed SB; Alrowaili ZA
    PLoS One; 2022; 17(10):e0271602. PubMed ID: 36301939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decoding selectivity: computational insights into AKR1B1 and AKR1B10 inhibition.
    Liu M; Qin X; Li J; Jiang Y; Jiang J; Guo J; Xu H; Wang Y; Bi H; Wang Z
    Phys Chem Chem Phys; 2024 Mar; 26(12):9295-9308. PubMed ID: 38469695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aldo-keto reductase family 1 member B1 inhibitors: old drugs with new perspectives.
    Liu J; Wen G; Cao D
    Recent Pat Anticancer Drug Discov; 2009 Nov; 4(3):246-53. PubMed ID: 19522700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Insight into the Pharmacological Importance of Atropine as the Potential Inhibitor of AKR1B1 via Detailed Computational Investigations: DFTs, ADMET, Molecular Docking, and Molecular Dynamics Studies.
    Ejaz SA; Aziz M; Ahmed A; Alotaibi SS; Albogami SM; Siddique F; Batiha GE
    Appl Biochem Biotechnol; 2023 Aug; 195(8):5136-5157. PubMed ID: 36847982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of human carbonyl reducing enzymes by plant anthrone and anthraquinone derivatives.
    Westermann M; Adomako-Bonsu AG; Thiele S; Çiçek SS; Martin HJ; Maser E
    Chem Biol Interact; 2022 Feb; 354():109823. PubMed ID: 35065925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aldo-keto reductases: Role in cancer development and theranostics.
    Nagini S; Kallamadi PR; Tanagala KKK; Reddy GB
    Oncol Res; 2024; 32(8):1287-1308. PubMed ID: 39055885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and evaluation of caffeic acid phenethyl ester-based inhibitors targeting a selectivity pocket in the active site of human aldo-keto reductase 1B10.
    Soda M; Hu D; Endo S; Takemura M; Li J; Wada R; Ifuku S; Zhao HT; El-Kabbani O; Ohta S; Yamamura K; Toyooka N; Hara A; Matsunaga T
    Eur J Med Chem; 2012 Feb; 48():321-9. PubMed ID: 22236472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitor selectivity between aldo-keto reductase superfamily members AKR1B10 and AKR1B1: role of Trp112 (Trp111).
    Zhang L; Zhang H; Zhao Y; Li Z; Chen S; Zhai J; Chen Y; Xie W; Wang Z; Li Q; Zheng X; Hu X
    FEBS Lett; 2013 Nov; 587(22):3681-6. PubMed ID: 24100137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aldo-Keto Reductases as Early Biomarkers of Hepatocellular Carcinoma: A Comparison Between Animal Models and Human HCC.
    Torres-Mena JE; Salazar-Villegas KN; Sánchez-Rodríguez R; López-Gabiño B; Del Pozo-Yauner L; Arellanes-Robledo J; Villa-Treviño S; Gutiérrez-Nava MA; Pérez-Carreón JI
    Dig Dis Sci; 2018 Apr; 63(4):934-944. PubMed ID: 29383608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of compound selectivity of aldo-keto reductases using differential scanning fluorimetry.
    Kabir A; Endo S; Toyooka N; Fukuoka M; Kuwata K; Kamatari YO
    J Biochem; 2017 Feb; 161(2):215-222. PubMed ID: 28003428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comprehensive computational approach for the identification of structure-based potential pharmacological candidates as selective AKR1B1 and AKR1B10 inhibitors: repurposing of purine alkaloids for the treatment of cancer.
    Aziz M; Ejaz SA; Tamam N; Siddique F
    J Biomol Struct Dyn; 2023; 41(16):7892-7912. PubMed ID: 36214620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aldo-Keto Reductase Family 1 Member B10 Inhibitors: Potential Drugs for Cancer Treatment.
    Huang L; He R; Luo W; Zhu YS; Li J; Tan T; Zhang X; Hu Z; Luo D
    Recent Pat Anticancer Drug Discov; 2016; 11(2):184-96. PubMed ID: 26844556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective Inhibition of Human AKR1B10 by
    Seliger JM; Cicek SS; Witt LT; Martin HJ; Maser E; Hintzpeter J
    Molecules; 2018 Nov; 23(11):. PubMed ID: 30469331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineering aldo-keto reductase 1B10 to mimic the distinct 1B15 topology and specificity towards inhibitors and substrates, including retinoids and steroids.
    Giménez-Dejoz J; Weber S; Fernández-Pardo Á; Möller G; Adamski J; Porté S; Parés X; Farrés J
    Chem Biol Interact; 2019 Jul; 307():186-194. PubMed ID: 31028727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological evaluation of steroidal derivatives as selective inhibitors of AKR1B10.
    Zhang W; Wang L; Zhang L; Chen W; Chen X; Xie M; Yan G; Hu X; Xu J; Zhang J
    Steroids; 2014 Aug; 86():39-44. PubMed ID: 24793566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selectivity determinants of inhibitor binding to the tumour marker human aldose reductase-like protein (AKR1B10) discovered from molecular docking and database screening.
    Zhao HT; Soda M; Endo S; Hara A; El-Kabbani O
    Eur J Med Chem; 2010 Sep; 45(9):4354-7. PubMed ID: 20538382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aldo-keto reductase family 1 member B10 promotes cell survival by regulating lipid synthesis and eliminating carbonyls.
    Wang C; Yan R; Luo D; Watabe K; Liao DF; Cao D
    J Biol Chem; 2009 Sep; 284(39):26742-8. PubMed ID: 19643728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Buparlisib is a novel inhibitor of daunorubicin reduction mediated by aldo-keto reductase 1C3.
    Bukum N; Novotna E; Morell A; Hofman J; Wsol V
    Chem Biol Interact; 2019 Apr; 302():101-107. PubMed ID: 30703376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.